Effect Of Sorafanib Combined EGCG On Proliferation Of HepG2 Cells And The Expression Of GRP78 And VEGFR-2 In HEPG2 Cells

Objective:To investigate the effect of sorafenib combined (-)-epigallocatec hin gallate (EGCG) and (Sorafenib) on the proliferation of HepG2 cells and the expression level of GRP78 and VEGFR-2 in HepG2 cells.Methods:The human hepatoma cell line HepG2 cultured in vitro. Hepato ma HepG2 cell was treated with EGCG,sorafenib and combined administration at different concentrations.The effect of EGCG and sorafenib on HepG2 prolife ration was examined by MTT assay.EGCG, sorafenib and sorafenib combined with EGCG acted on HepG2 cell line after 24h, the expression of GRP78 and VEGFR-2 was analyzed by ELISA and Western blot.Results:The MTT results showed that HepG2 proliferation was inhibited after treated with different concentrations of EGCG and sorafenib after 24 hour s. Different concentrations of sorafenib effecting on HepG2 cells after 24h found ed that the proliferation of HepG2 cell was inhibited. Inhibition rate was positi vely correlated with drug concentration. The IC50 of EGCG and Sorafenib was 60.2±2.02mg/L and 8.42±0.37ummol/L,which calculated by SPSS. According t o IC50 of EGCG and Sorafenib, HepG2 cells was treated with EGCG60mg/L, sorafenib8.5umol/L and sorafenib 8.5umol/L combined with EGCG 60mg/L. Th e MTT was used to detect the inhibition rate, it showed that the inhibition rat e of drug combination group was significantly higher than that of the single dr ug group (P<0.05). ELISA method was used to detect the expression of VEGF R-2 and GRP78, the results showed that the expression of VEGFR-2 and GRP78 was significantly lower in the treatment groups than control (P<0.01), and sig nificantly lower in combination group than single drug group (P<0.01), and lo wer in sorafenib group than the EGCG group(P< 0.01). Furthermore, the expre ssion of VEGFR-2 and GRP78 was detected by Western blot, the results show ed that the expression of VEGFR-2 and GRP78 was significantly lower in the tr eatment groups than control (P<0.01), and significantly lower in combination gr oup than single drug group (P<0.01), and lower in sorafenib group than the E GCG group(P< 0.01).Conclusion:1.The effect of EGCG combined with Sorafenib on the inhibition of protein GR P78 and VEGFR-2 in human hepatocellular carcinoma is better than single Sorafeni b;2. EGCG combined with Sorafenib can inhibit the proliferation of HepG2, and it s mechanism may be related to the inhibition of GRP78 and VEGFR-2’s expressi on.